Navigation Links
YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
Date:2/10/2011

will generate positive efficacy and safety data in future clinical trials; that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Summary financial statements attached:

YM BIOSCIENCES INC. Interim Consolidated Balance Sheets (Expressed in Canadian dollars, unless otherwise noted) ------------------------------------------------------------------------- December 31, June 30, 2010 2010 ------------------------------------------------------------------------- (Unaudited) Assets Current assets: Cash and cash equivalents $ 25,261,196 $ 19,460,141 Short-term deposits 53,451,681 26,184,991 Accounts receivable 203,163 161,184 Prepaid expenses 494,678 237,962 ----------------------------------------------------------------------- 79,410,718 46,044,278 Property and equipment 109,065 84,775 Intangible assets 9,391,706 11,645,714 ------------------------------------------------------------------------- $ 88,911,489 $ 57,774,767 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Liabilities and Shareholders' Equity Current liabilities: Accounts payable $ 1,411,962 $ 699,277 Accrued liabilities 3,524,184 2,085,824 Deferred revenue 594,072 1,523,916 ----------------------------------------------------------------------- 5,530,218 4,309,017 Deferred revenue 2,128,758 1,650,909 Shareholders' equity: Share capital 248,203,430 203,498,239 Share purchase warrants 1,378,324 1,473,246 Contributed surplus 14,916,826 14,088,671 Deficit (183,246,067) (167,245,315) ----------------------------------------------------------------------- 81,252,513 51,814,841 Basis of presentation Commitments -------------
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
3. YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
4. Ardea Biosciences Prices Public Offering of Common Stock
5. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
6. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
7. Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students
8. YM BioSciences Closes Public Offering of Common Shares
9. YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING
10. Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen
11. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Two champions of ... their sponsorship of an annual competition for middle and ... access to, innovative STEM study. The competition presents students ... Tests of Engineering Aptitude, Mathematics, and Sciences is ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... DuPont Senior,Vice President and Chief Science & Technology Officer ... in the formation of global,policy during a discussion at ... of science is to inform the policymaking process, to ... limits of what is,knowable, and what is possible," Chowdhry ...
... Massive Rebuilding Effort for Tornado-Torn ... Health Care Facility, ... struggle to rebuild following a devastating 2007 tornado,Siemens has announced that, ... Ga. facility with a new MAGNETOM ESSENZA, worth,approximately $800,000., Siemens ...
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today ... trial of a second generation oral niacin receptor agonist,under ... the,treatment of atherosclerosis and other disorders. The initiation of ... are very pleased with the progress of this collaboration,investigating ...
Cached Biology Technology:DuPont Chief Science & Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2DuPont Chief Science & Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 3A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 2Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc. 3
(Date:4/18/2014)... of researchers led by a University of California, Riverside ... $7.5 million Department of Defense grant to uncover fundamental ... for the predictable design of light-weight, tough and strong ... from plants and animals, including the mantis shrimp, toucan ... have constructed over millions of years and coming up ...
(Date:4/17/2014)... Respiratory syncytial virus (RSV) is a leading cause ... in very young and elderly populations. Despite great ... cells through the fusion protein RSV F, which ... that prevent bundle formation limit RSV infection in ... degradation. In this issue of the Journal ...
(Date:4/17/2014)... Foundation has been named awardee of a three-year ... Defense Spinal Cord Injury Research Program. Gail Forrest, ... double-blinded, controlled, multi-site clinical trial, which will test ... spinal cord injury. Dr. Forrest is assistant director ... Foundation. Two additional sites will participate - the ...
Breaking Biology News(10 mins):Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2
... El Nio was associated with higher mortality for eggs and ... could be worsened by continuing global climate change, according to ... PLoS ONE . The El Nio Southern Oscillation brought ... major nesting sites in the area. The researchers, led by ...
... 25, 2012 Babolat, international specialized tennis ... "Babolat Play & Connect," at the French Open. The ... nearly infinite potential. Welcome to the tennis of the ... first interactive racquet with organized demonstrations featuring amateur players ...
... in German . In the animal world, ... is the most beautiful. A well-known example is the peacock. The ... research team at Bielefeld University headed by the evolutionary biologist Dr. ... involved in mate choice among locusts. The male Siberian locust ( ...
Cached Biology News:"Babolat Play & Connect" - Worldwide Exclusive Event at the French Open 2"Babolat Play & Connect" - Worldwide Exclusive Event at the French Open 3"Babolat Play & Connect" - Worldwide Exclusive Event at the French Open 4A mating dance with Popeye arms 2
Request Info...
...
Collected from sexually mature mice....
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
Biology Products: